Better Targeting, Delivery of RNAi Therapies
Forgoing the Comforts of Small Molecules and Antibodies, Some Drug Developers Are Setting Their Sights on RNAi-Based Therapeutics
Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Biopharma Payment Crackdown
Manufacturers of branded and generic drugs, biologicals, devices, or medical supplies subject to reimbursement under Medicare, Medicaid, or the Children's Health Insurance Program now must report to the federal government data on their payments to physicians or teaching hospitals starting in August, under new regulations. The rules—required under section 6002 of President Obama’s Affordable Care Act (ACA)—require manufacturers to report their data on payments or “transfers of value” by March 31, 2014, and every year thereafter to the Centers for Medicare & Medicaid Services (CMS). (For more on the new regulations, click here.) What kind of an effect do you think this will have on the biopharma industry?